Towards response-adapted neoadjuvant breast cancer treatment

Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases.

Breast (Edinburgh, Scotland)·2026

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

The oncologist·2026

Real-world treatment patterns and outcomes in hormone receptor-positive, HER2-low metastatic breast cancer, 2018-2023: a retrospective, observational, US cohort study.

Breast cancer research and treatment·2026

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

The Lancet. Oncology·2026

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

Breast cancer research and treatment·2026

Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial.

Breast (Edinburgh, Scotland)·2026

Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

The Lancet. Oncology·2026

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

The Lancet. Oncology·2026

Advancing oncology education in low-income and middle-income African settings: global insights for local action.

The Lancet. Oncology·2026

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

The Lancet. Oncology·2026

Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

The Lancet. Oncology·2026

Conformal Thermoreversible Gelatin-Based Gel for High-Fidelity Electrophysiological Recording and Acute Peripheral Nerve Interfacing.

Advanced materials (Deerfield Beach, Fla.)·2026

A Glucose-Responsive Hydrogel with Multifunctional Properties for Accelerated Diabetic Wound Healing.

Biomaterials research·2026

Generation of alveolar organoids from human induced pluripotent stem cells using a stirred-tank bioreactor.

Frontiers in bioengineering and biotechnology·2026

Human iPSC-derived mesenchymal progenitor cell sheets promote tissue formation after xenotransplantation.

iScience·2026

Bioprinted vascularized soft-tissue flaps with an integrated arterial-venous loop.

Cell biomaterials·2026

Co-localization of TAZ and H2A.Z up-regulates IL-6 expression in alveolar epithelial cells to polarize M2 cells to alleviate hypoxia-induced lung injury.

Genes & diseases·2026

Related Experiment Videos

Towards response-adapted neoadjuvant breast cancer treatment

Related Concept Videos

Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases.

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

Real-world treatment patterns and outcomes in hormone receptor-positive, HER2-low metastatic breast cancer, 2018-2023: a retrospective, observational, US cohort study.

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial.

Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

Advancing oncology education in low-income and middle-income African settings: global insights for local action.

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

Conformal Thermoreversible Gelatin-Based Gel for High-Fidelity Electrophysiological Recording and Acute Peripheral Nerve Interfacing.

A Glucose-Responsive Hydrogel with Multifunctional Properties for Accelerated Diabetic Wound Healing.

Generation of alveolar organoids from human induced pluripotent stem cells using a stirred-tank bioreactor.

Human iPSC-derived mesenchymal progenitor cell sheets promote tissue formation after xenotransplantation.

Bioprinted vascularized soft-tissue flaps with an integrated arterial-venous loop.

Co-localization of TAZ and H2A.Z up-regulates IL-6 expression in alveolar epithelial cells to polarize M2 cells to alleviate hypoxia-induced lung injury.

Related Experiment Videos

Towards response-adapted neoadjuvant breast cancer treatment

Related Concept Videos

Related Articles